Effects of decomplementation on mercuric chloride-induced glomerulonephritis in Brown-Norway rats. 1982

M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet

The course of mercuric chloride-induced immune glomerulonephritis is characterized by complement activation, intensive proteinuria, linear and then granular IgG and C3 deposits in the glomeruli. To assess the role of complement activation in the occurrence of the disease, decomplementation was achieved by intravenous injections of cobra venom factor in rats injected with mercuric chloride. In these animals, proteinuria still appeared while rats were decomplemented by cobra venom factor through the alternative pathway. These rats exhibited linear IgG deposits without detectable C3 deposits. In the rats injected with cobra venom factor alone, no proteinuria, no classical pathway complement activation and no renal IgG or C3 deposits were observed. Therefore, in Brown-Norway rats intoxicated with mercuric chloride, proteinuria appears to be at least in part complement independent.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008297 Male Males
D008627 Mercuric Chloride Mercury chloride (HgCl2). A highly toxic compound that volatizes slightly at ordinary temperature and appreciably at 100 degrees C. It is corrosive to mucous membranes and used as a topical antiseptic and disinfectant. Mercury Dichloride,Corrosive Sublimate,HgCl2,Mercuric Perchloride,Mercury Bichloride,Mercury Perchloride,Sublimate,Bichloride, Mercury,Chloride, Mercuric,Dichloride, Mercury,Perchloride, Mercuric,Perchloride, Mercury,Sublimate, Corrosive
D008628 Mercury A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D011914 Rats, Inbred BN An inbred strain of rat that is widely used in a variety of research areas such as the study of ASTHMA; CARCINOGENESIS; AGING; and LEUKEMIA. Rats, Inbred Brown Norway,Rats, BN,BN Rat,BN Rat, Inbred,BN Rats,BN Rats, Inbred,Inbred BN Rat,Inbred BN Rats,Rat, BN,Rat, Inbred BN
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3

Related Publications

M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
January 1984, Thrombosis research,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
August 1979, Laboratory investigation; a journal of technical methods and pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
January 1986, Toxicologic pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
September 2003, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
July 1992, Laboratory investigation; a journal of technical methods and pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
January 1987, Progress in clinical and biological research,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
August 1995, Laboratory investigation; a journal of technical methods and pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
August 2003, Experimental and molecular pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
February 1995, Laboratory investigation; a journal of technical methods and pathology,
M Capron, and C Bascou, and M C Vial, and J Grossetete, and N Hinglais, and J F Girard, and P Druet
March 1984, Clinical immunology and immunopathology,
Copied contents to your clipboard!